FDA Approves Viatris' RYZUMVI for Presbyopia in Adults
Image
Pittsburgh – October 16, 2026 -- The U.S. Food and Drug Administration (FDA) has approved Viatris Inc.'s RYZUMVI (phentolamine ophthalmic solution 0.75%) for the treatment of presbyopia in adults, adding a second indication to a product already on the U.S. market.
RYZUMVI is currently approved in the United States for pharmacologically-induced mydriasis and is the only commercially available FDA-approved product for that use. The presbyopia approval expands its label beyond that use.
Viatris Is Exploring a U.S. Commercialization Partner for the Presbyopia Indication
Viatris said it is exploring the potential for a partner in the United States to commercialize RYZUMVI for presbyopia. The company disclosed no partner, timeline or financial terms.